WAVE LIFE SCIENCES LTD. Total Liabilities

Latest as of March 2026: €71.81 Million EUR ≈ $83.96 Million USD

WAVE LIFE SCIENCES LTD. total liabilities. Based on the latest financial reports, WAVE LIFE SCIENCES LTD. (1U5) has total liabilities worth €71.81 Million EUR (≈ $83.96 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See WAVE LIFE SCIENCES LTD. (1U5) liquidity interval to measure how many days the company can operate on defensive assets alone.

Total Liabilities of WAVE LIFE SCIENCES LTD. (2021–2025)

Total liabilities of WAVE LIFE SCIENCES LTD. from 2021 to 2025. This chart illustrates how WAVE LIFE SCIENCES LTD.'s total liabilities have evolved over time, based on quarterly financial data.

WAVE LIFE SCIENCES LTD. Competitors by Total Liabilities

The table below lists competitors of WAVE LIFE SCIENCES LTD. ranked by their total liabilities.

Company Country Total Liabilities
Shanghai Smith Adhesive New
SHG:603683
China CN¥1.55 Billion
ORIENT SECUR.CO.LTD.H YC1
F:OS9
Germany €431.65 Billion
Molinos Agro SA
BA:MOLA
Argentina AR$870.57 Billion
Alight Inc
NYSE:ALIT
USA $3.53 Billion
Plan B Media Public Company Limited
BK:PLANB-R
Thailand ฿7.44 Billion
Zhejiang Vie Science & Technology Co Ltd
SHE:002590
China CN¥2.91 Billion
Sam Engineering Equipment
KLSE:9822
Malaysia RM572.53 Million
Formosan Union Chemical Corp
TW:1709
Taiwan NT$3.09 Billion

Liability Composition Analysis (2021–2025)

This chart breaks down WAVE LIFE SCIENCES LTD.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see WAVE LIFE SCIENCES LTD. total assets.

Liquidity & Leverage Metrics

WAVE LIFE SCIENCES LTD. Total Liabilities Ratios Explained

WAVE LIFE SCIENCES LTD. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 11.26 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.14 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.12 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how WAVE LIFE SCIENCES LTD.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for WAVE LIFE SCIENCES LTD. (2021–2025)

The table below shows the annual total liabilities of WAVE LIFE SCIENCES LTD. from 2021 to 2025.

Year Total Liabilities Change
2025-12-31 €120.14 Million
≈ $140.46 Million
-15.80%
2024-12-31 €142.69 Million
≈ $166.82 Million
-39.36%
2023-12-31 €235.32 Million
≈ $275.11 Million
+22.90%
2022-12-31 €191.48 Million
≈ $223.86 Million
+9.72%
2021-12-31 €174.51 Million
≈ $204.02 Million
--

About WAVE LIFE SCIENCES LTD.

F:1U5 Germany Biotechnology
Market Cap
$714.18 Million
€610.88 Million EUR
Market Cap Rank
#10140 Global
#1226 in Germany
Share Price
€3.18
Change (1 day)
+2.58%
52-Week Range
€2.62 - €17.50
All Time High
€46.63
About

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent diso… Read more